

Ref No. NLL/CS/2011-1006

Dated: 12.08.2011

1. National Stock Exchange of India Limited
'G' Block, Exchange Plaza, Bandra Kurla Complex,
Bandra (East), MUMBAI - 400 051.
2. Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers, Dalal Street,
MUMBAI - 400 001.

Sub: Compliance under Clause 41 the Listing Agreement.

Sirs,

Pursuant to Clause 41 of the Listing Agreement, please find enclosed herewith a copies of the Unaudited Financial Results for the quarter ended 30th June, 2011 and Audited Financial Results of the company for the year ended 31st March, 2011, as approved by the Board of Directors in their meeting held on even date i.e. 12th August, 2011.

Kindly take the same on record and oblige.

Thanking you,

Yours truly,
For Nectar Lifesciences Limited

(Sunder Lal)
Company Secretary

Encl. as above

CC:-

Societe de la Bourse de Luxembourg S.A.
BP 165, L-2011 Luxembourg,
Telephone : (00352) 47 79 38-1
Fax: (00352) 47 32 98

S. No	PARTICULARS	Quarter ended 30.06.2011	Quarter ended 30.06.2010	Year Ended 31.03.2011	Year Ended 31.03.2010	Year Ended 31.03.2011	Year Ended 31.03.2010
		Unaudited (Stand-alone)	Unaudited (Stand-alone)	Audited (Stand-alone)	Audited (Stand-alone)	Audited (Consolidated)	Audited (Consolidated)
1.	Gross Sales/Income from Operations	21907.37	19138.07	111577.03	88582.17	111577.03	88582.17
	Less : Excise Duty	1017.83	1013.24	6032.19	4002.26	6032.19	4002.26
	Net Sales / Income from Operations	20889.54	18124.83	105544.84	84579.91	105544.84	84579.91
	Other Operating Income	240.58	79.51	661.44	409.59	661.44	409.59
	Total Operating Income	21130.12	18204.34	106206.28	84989.50	106206.28	84989.50
2.	Expenditure						
	a. (Increase)/decrease in stock in trade	(170.04)	(332.85)	(3162.81)	939.51	(3162.81)	939.51
	b. Consumption of Raw Material	13432.48	11520.45	74269.80	53491.67	74269.80	53491.67
	c. Employees Cost	1240.35	876.70	3716.81	3187.70	3716.81	3193.42
	d. Depreciation	1225.34	1125.64	4609.59	3874.64	4609.59	3874.64
	e. Other Expenditure	2141.07	1653.74	8694.38	7457.01	8665.84	7460.21
	Total Expenditure	17869.20	14843.68	88127.77	68950.53	88099.23	68959.45
3.	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	3260.92	3360.66	18078.51	16038.97	18107.05	16030.05
4.	Other Income	0.08	5.00	1345.58	1485.73	1345.58	1530.19
5.	Profit before Interest & Exceptional Items (3+4)	3261.00	3365.66	19424.09	17524.70	19452.63	17560.24
6.	Interest	1960.36	1276.59	7408.40	6028.44	7408.85	6030.24
7.	Profit after Interest but before Exceptional Items (5-6)	1300.64	2089.07	12015.69	11496.26	12043.78	11530.00
8.	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
9.	Profit from ordinary activities before tax (7+8)	1300.64	2089.07	12015.69	11496.26	12043.78	11530.00
10.	Tax Expenses	178.66	521.12	1734.68	2298.81	1734.68	2301.04
11.	Net Profit from ordinary activities after tax (9-10)	1121.98	1567.95	10281.01	9197.45	10309.10	9228.96
12.	Extraordinary Item (net of tax expense)	0.00	0.00	0.00	0.00	0.00	0.00
13.	Net Profit for the period (11-12)	1121.98	1567.95	10281.01	9197.45	10309.10	9228.96
14.	Paid up Equity Share Capital (Face Value per share : Re.1/-)	2242.61	2242.61	2242.61	2242.61	2242.61	2242.61
16.	Earnings per Share (EPS)						
	Basic EPS before Extraordinary items	0.50	0.70	4.63	5.81	4.65	5.83
	Diluted EPS before Extraordinary items	0.50	0.56	4.63	4.28	4.65	4.29
	Basic EPS after Extraordinary items	0.50	0.70	4.63	5.81	4.65	5.83
	Diluted EPS after Extraordinary items	0.50	0.56	4.63	4.28	4.65	4.29
17.	Public Shareholding						
	- Number of Shares	124896970	126119330	124969970	126119330	124969970	126119330
	- Percentage of Shareholding	55.69	56.24	55.73	56.24	55.73	56.24
18.	Promoters and Promoter Group Shareholding						
	a) Pledged/Encumbered						
	- Number of Shares	0	0	0	0	0	0
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	0.00	0.00	0.00	0.00	0.00	0.00
	- Percentage of Shares (as a % of the total share capital of the company)	0.00	0.00	0.00	0.00	0.00	0.00
	b) Non-encumbered						
	- Number of Shares	99364000	98141640	99291000	98141640	99291000	98141640
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the company)	44.31	43.76	44.27	43.76	44.27	43.76

Statement of Assets and Liabilities


(Rs in Lacs)

PARTICULARS	As at 31.03.2011 Audited (Stand-alone)	As at 31.03.2010 Audited (Stand-alone)	As at 31.03.2011 Audited (Consolidated)	As at 31.03.2010 Audited (Consolidated)
SHAREHOLDERS' FUND				
(a) Capital	2242.61	2242.61	2242.61	2242.61
(b) Reserves and Surplus	69875.75	59855.37	69870.73	59822.26
LOAN FUNDS	79599.57	60089.22	79599.57	60089.22
DEFERRED TAX LIABILITY	5080.56	5018.59	5080.56	5018.59
Total	156798.49	127205.79	156793.47	127172.68
FIXED ASSETS	81867.57	68277.36	81867.57	68277.36
INVESTMENTS	538.18	2569.29	538.18	2105.73
CURRENT ASSETS, LOANS & ADVANCES				
(a) Inventories	47088.48	39635.36	47088.48	39635.36
(b) Sundry Debtors	31112.85	22245.45	31112.85	22245.45
(c) Cash and Bank balances	3257.49	3051.72	3257.49	3478.98
(d) Other Current Assets	2204.62	2646.56	2204.62	2646.56
(e) Loans and Advances	15189.84	9644.01	15186.56	9655.31
Less: Current Liabilities and Provisions				
(a) Current Liabilities	15520.81	14371.41	15522.55	14379.52
(b) Provisions	8942.73	6496.30	8942.73	6496.30
Miscellaneous Expenditure(Not written off or adjusted)	3.00	3.75	3.00	3.75
Total	156798.49	127205.79	156793.47	127172.68

Notes:

- The above financial results were reviewed by Audit Committee on 12.08.11 and approved by the Board in its meeting held on even date i.e. 12.08.11 and further limited reviewed by the Statutory Auditors of the Company.
 - The company is exclusively in the pharmaceutical business segment.
 - On 26.04.2011, the company had repaid FCCB amounting to US\$ 49.7343 millions inclusive of premium of US\$ 16.7343 millions due thereon. Interest for the year 2010-11 includes Rs. 1894 lacs, as premium accrued on FCCB, which has been ascertained on repayment of FCCB on 26.04.2011. Since, the FCCBs have been fully redeemed, therefore, the diluted EPS has not been calculated for the year 2010-11.
 - The EPS of last year was high due to the weighted average of shares taken for the allotment of - equity shares on Preferential basis and equity shares underlying GDRs, Issue on 20.02.2010 and 26.02.2010, respectively.
 - The Board of Directors has recommended the Final Dividend of Re. 0.10/- per equity share (10% on the face value of Re. 1/- per equity share) to the Members of the Company, out of profits of the Company for the financial year 2010-11.
 - Status of Complaints:
 - Pending at the beginning of Quarter - Nil
 - Received During the Quarter - 5
 - Disposed Off During the Quarter - 5
 - Pending at the end of Quarter - Nil
- Dated: 12.08.2011
Place: Chandigarh

By Order of the Board of Directors
of Nectar Lifesciences Limited
S/-
(Dinesh Dua)
Chief Executive Officer & Director

Certified to be true copy
For Nectar Lifesciences Limited

Sunder Lal
Company Secretary